Congresses and Publications

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia

Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrӧm macroglobulinemia

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenstrӧm macroglobulinemia (MYD88WT WM)

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia (WM)

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study) Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type Waldenstrӧm macroglobulinemia

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstrӧm macroglobulinemia Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study) Updated results of the ASPEN trial from a cohort of patients with wild-type MYD88 Waldenstrӧm macroglobulinemia

Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)

Safety and efficacy of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA phase 2 study)

Association between use of antibiotics and clinical outcomes with tislelizumab monotherapy DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Effects of tislelizumab monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma RATIONALE 304: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for non-squamous non-small cell lung cancer in patients who are smokers vs non-smokers RATIONALE 307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer in patients who were smokers versus non-smokers Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer

Association between use of antibiotics (ATB) and clinical outcomes with tislelizumab (tisle) monotherapy DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial Effects of tislelizumab (TIS) monotherapy on health-related quality of life in patients with previously treated unresectable hepatocellular carcinoma (HCC) RATIONALE 304: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first‑line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers RATIONALE 307: tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)

First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia (CLL) in the United States Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results

A real-world study to assess the association of cardiovascular adverse events with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukemia First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Zanubrutinib in patients with B-cell malignancies intolerant to ibrutinib and/or acalabrutinib Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE-303: a global phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study

RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results